Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 4, 2012, Pages 425-435

  Jasny, Edith ^a   Geer, Suzanne ^a   Frank, Ines ^a   Vagenas, Panagiotis ^a   Aravantinou, Meropi ^a   Salazar, Andres M ^b   Lifson, Jeffrey D ^c   Piatak Jr , Michael ^c   Gettie, Agegnehu ^d   Blanchard, James L ^e   Robbiani, Melissa ^a  

^a POPULATION COUNCIL   (United States)

^b Oncovir   (United States)

^c SAIC FREDERICK INC   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

antiretroviral therapy; mucosal immunity; peripheral immunity; SIV

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; EMTRICITABINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HILTONOL; IMMUNOLOGIC AGENT; MESSENGER RNA; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; INOCULATION; LONG TERM CARE; MALE; MEMORY T LYMPHOCYTE; MOUTH; MUCOSAL IMMUNITY; MYELOID DENDRITIC CELL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENINE; ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; IMMUNITY, MUCOSAL; IMMUNOPHENOTYPING; INJECTIONS, SUBCUTANEOUS; MACACA MULATTA; MALE; ORGANOPHOSPHONATES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T-LYMPHOCYTE SUBSETS;

EID: 84870293288     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318266be53     Document Type: Article

References (66)

1. Desrosiers RC. The simian immunodeficiency viruses. Annu Rev Immunol. 1990;8:557-578. (Pubitemid 20135639)
2. Desrosiers RC. Non-human primate models for AIDS vaccines. AIDS. 1995;9(suppl A):S137-S141.
3. Van Rompay KK. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 2010;85:159-175.
4. Van Rompay KK. Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments. AIDS Rev. 2005;7:67-83. (Pubitemid 41079018)
5. Franchini G, Nacsa J, Hel Z, et al. Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. Vaccine. 2002;20 (suppl 4)A52-A60. (Pubitemid 35449406)
6. Sellier P, Mannioui A, Bourry O, et al. Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One. 2010;5:e10570.
7. Clements JE, Gama L, Graham DR, et al. A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS. 2011;6:37-42.
8. George MD, Reay E, Sankaran S, et al. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol. 2005;79:2709-2719. (Pubitemid 40270549)
9. Hill A, Sawyer W. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med. 2009;10:527-535.
10. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230-2240.
11. Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fuma-rate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs. 2010;70:2315-2338.
12. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricita-bine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-1556.
13. Gay CL, Mayo AJ, Mfalila CK, et al. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011;25:941-949.
14. Perry CM. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. Drugs. 2009;69:843-857.
15. Shen A, Zink MC, Mankowski JL, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol. 2003;77:4938-4949. (Pubitemid 36402842)
16. Murry JP, Higgins J, Matthews TB, et al. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol. 2003;77:1120-1130. (Pubitemid 36055534)
17. Vagenas P, Aravantinou M, Williams VG, et al. A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One. 2010;5:e12891.
18. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144-3160.
19. Lifson JD, Rossio JL, Arnaout R, et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol. 2000;74:2584-2593. (Pubitemid 30117567)
20. Rosenwirth B, ten Haaft P, Bogers WM, et al. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol. 2000;74:1704-1711. (Pubitemid 30434026)
21. Verhoeven D, Sankaran S, Silvey M, et al. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol. 2008;82:4016-4027. (Pubitemid 351521237)
22. Stahl-Hennig C, Steinman RM, Tenner-Racz K, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science. 1999;285:1261-1265. (Pubitemid 29398612)
23. Tenner-Racz K, Hennig CS, Uberla K, et al. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci U S A. 2004;101:3017-3022. (Pubitemid 38327727)
24. Suh YS, Park KS, Sauermann U, et al. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase. Vaccine. 2008;26:6690-6698.
25. Animal Welfare Act and Regulation. Code of Federal Regulations. Chapter 1. In: Animals and Animal Products. Beltsville, MD: US Department of Agriculture.
26. Vagenas P, Williams VG, Piatak M Jr, et al. Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr. 2009;52:433-442.
27. Cline AN, Bess JW, Piatak M Jr, et al. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol. 2005;34:303-312. (Pubitemid 41179592)
28. Smith SM, Holland B, Russo C, et al. Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. AIDS Res Hum Retrovir. 1999;15:1691-1701.
29. Gauduin MC. Intracellular cytokine staining for the characterization and quantitation of antigen-specific T lymphocyte responses. Methods. 2006; 38:263-273.
30. Crostarosa F, Aravantinou M, Akpogheneta OJ, et al. A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One. 2009;4:e8060.
31. Frank I, Santos JJ, Mehlhop E, et al. Presentation of exogenous whole inactivated simian immunodeficiency virus by mature dendritic cells induces CD4+ and CD8+ T-cell responses. J Acquir Immune Defic Syndr. 2003;34:7-19. (Pubitemid 37100106)
32. Vachot L, Williams VG, Bess JW Jr, et al. Candida albicans-induced DC activation partially restricts HIV amplification in DCs and increases DC-to-T-cell spread of HIV. J Acquir Immune Defic Syndr. 2008;48:398-407.
33. Kenney J, Aravantinou M, Singer R, et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One. 2011;6:e15835.
34. Stanford University HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu. Accessed July 30, 2012.
35. Van Rompay KK, Johnson JA, Blackwood EJ, et al. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology. 2007;4:25.
36. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49-62.
37. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
38. Ortiz GM, Hu J, Goldwitz JA, et al. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol. 2002;76:411-415. (Pubitemid 33139026)
39. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
40. Lewis MG, Norelli S, Collins M, et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology. 2010;7:21.
41. Van Rompay KK, Cherrington JM, Marthas ML, et al. 9-[2-(Phospho- nomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother. 1996;40:2586-2591. (Pubitemid 26367649)
42. Van Rompay KK, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl] adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol. 2000;74:1767-1774. (Pubitemid 30434034)
43. Veazey RS, Tham IC, Mansfield KG, et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol. 2000;74:57-64. (Pubitemid 30002883)
44. Mattapallil JJ, Douek DC, Hill B, et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434:1093-1097. (Pubitemid 40663481)
45. Wijewardana V, Soloff AC, Liu X, et al. Early myeloid dendritic cell dysregulation is predictive of disease progression in simian immunodeficiency virus infection. PLoS Pathog. 2010;6:e1001235.
46. Macatonia SE, Lau R, Patterson S, et al. Dendritic cell infection, depletion and dysfunction in HIV infected individuals. Immunology. 1990;71:38-45. (Pubitemid 20296069)
47. Pacanowski J, Kahi S, Baillet M, et al. Reduced blood CD123+ (lym-phoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood. 2001;98:3016-3021.
48. Sabado RL, O'Brien M, Subedi A, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood. 2010;116:3839-3852.
49. Barratt-Boyes SM, Wijewardana V, Brown KN. In acute pathogenic SIV infection plasmacytoid dendritic cells are depleted from blood and lymph nodes despite mobilization. J Med Primatol. 2010;39:235-242.
50. Easlick J, Szubin R, Lantz S, et al. The early interferon alpha subtype response in infant macaques infected orally with SIV. J Acquir Immune Defic Syndr. 2010;55:14-28.
51. Abel K, Pahar B, Van Rompay KK, et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol. 2006;80:6357-6367. (Pubitemid 43927439)
52. Milush JM, Stefano-Cole K, Schmidt K, et al. Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques. J Virol. 2007;81:6175-6186. (Pubitemid 46878024)
53. Durudas A, Chen HL, Gasper MA, et al. Differential innate immune responses to low or high dose oral SIV challenge in rhesus macaques. Curr HIV Res. 2011;9:276-288.
54. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res. 2011; 317:620-631.
55. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol. 1997;61:246-257. (Pubitemid 27149903)
56. Lane BR, King SR, Bock PJ, et al. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology. 2003;307:122-134. (Pubitemid 36349442)
57. Boulware DR, Meya DB, Bergemann TL, et al. Antiretroviral therapy down-regulates innate antiviral response genes in patients with AIDS in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2010;55:428-438.
58. Bergmeier LA, Wang Y, Lehner T. The role of immunity in protection from mucosal SIV infection in macaques. Oral Dis. 2002;8(suppl 2):63-68. (Pubitemid 41758943)
59. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells [see comments]. Science. 1995;270:1811-1815.
60. Lifson JD, Piatak M Jr, Cline AN, et al. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol. 2003;32:201-210. (Pubitemid 37021245)
61. Kubo M, Nishimura Y, Shingai M, et al. Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease. J Virol. 2009;83:7099-7108.
62. Jin X, Ogg G, Bonhoeffer S, et al. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Mol Med. 2000;6:803-809.
63. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antire-troviral therapy. J Virol. 1999;73:6721-6728. (Pubitemid 29327855)
64. Casazza JP, Betts MR, Picker LJ, et al. Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol. 2001;75:6508-6516. (Pubitemid 32578170)
65. Sester U, Sester M, Kohler H, et al. Maintenance of HIV-specific central and effector memory CD4 and CD8 T cells requires antigen persistence. AIDS Res Hum Retroviruses. 2007;23:549-553. (Pubitemid 46700888)
66. Connick E, Bosch RJ, Aga E, et al. Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr. 2011;58:1-8.